GT Biopharma, Inc. (OTCMKTS: GTBP) is setting the stage for a strong day in the market today after announcing positive data from and the advancement of a Phase I/II clinical trial. Here’s what’s going on:
GTBP Announces The Advancement Of Its TriKE Clinical Trial
In the press release, GT Biopharma said that it has completed the treatment of patients enrolled at Dose Levels one and two in the dose-escalation Phase one portion of its GTB-3550 TriKe Phase I/II clinical trial.
Moreover, the company said that it has begun enrolling patients for Dose Level 3 in its clinical trial. Not to mention, the data from Dose Levels one and two proved to be overwhelmingly positive.
GTBP said that the first patient treated with GTB-3550 in the trial achieved stable disease. The achievement was measured by the number of AML blasts observed in the patient’s bone marrow before and after treatment.
Moreover, the company saw an increase in the patient’s total NK cell population that it believes is attributable to the IL-15 component of GTB-3550. There was also no observed appreciable increase of any hyper-active T-cell population.
Importantly, none of the four patients treated with GTB-3550 to date have experienced constitutional adverse reactions or other reactions that are generally seen in patients who receive immuno-oncology therapeutics.
In a statement, Mr. Anthony Cataldo, Chairman and CEO at GTBP, had the following to offer:
“We are pleased to be able to advance to the next higher dose level in our first-in-human trial of GTB-3550, and hope to continue to see additional signals of efficacy and safety at the higher dose level.”
This News Is Huge
The news released by GT Biopharma proved to be overwhelmingly positive. So far, the Phase I portion of the clinical trial is doing what it was intended to do. The data is showing that GTB-3550 is safe and tolerable in 100% of patients it has been provided to thus far. Moreover, the trial has shown signs of efficacy in severely ill AML patients.
Should GTBP bring the treatment to market, it would be tapping into a massive opportunity. By the year 2025, the AML treatment market is expected to grow to be worth approximately $2.2 billion. With incredible early-stage success in a seriously ill patient population that has few therapeutic options GTBP is a stock that should be watched very closely.
Get Free Alerts
Join our free mailing list to receive stock alerts!
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and GT Biopharma, CNA Finance has been hired for a period beginning on 3/1/20 and ending on 4/31/20 to conduct digital advertising and marketing and publicly disseminate information about GTBP via Websites and Email. We have an agreement and have been paid fifteen thousand dollars via bank wire transfer to cover the cost of content production. The agreement was extended on May 25 and will run through June 24, 2020. For this extension, GTBP paid CNA Finance an additional fifteen thousand dollars. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and GT Biopharma has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.